Abstracts

Rationale: Perampanel is a selective, non-competitive, AMPA receptor antagonist that is approved for adjunctive treatment of refractory partial-onset seizures in patients with epilepsy aged 12 years and older The aim of this study is to evaluate the efficacy and tolerability of Perampanel as adjunctive treatment in patients with focal refractory epilepsy.Methods: This is a restrospective observational study to describe the clinical data of 124 patients across two hospitals in Spain receiving Perampanel as adjuvant treatment in patients with refractory epilepsy. Of those 124 patients, we evaluated safety and efficacy at 3 (76 patients) 6 months (TBD) and last follow up (TBD)Results: From a total of 124 patients, 65% of them were female (35% male) with an average age of 39 years old (P25-75: 30-49) and average time in epilepsy of 25 years (P25-75: 15-35). The etiology was focal in 72%. Average number of concomitant antiepileptic drugs at baseline was 2.8 (P25-75: 2-3). Responder rate was 41% with 6.5 % of patients free of seizures. Adverse events were recorded in 47% of patients. Of those, dizziness (15%), aggressiveness (12%), somnolence (12%) and irritability (8%) were the most common.Conclusions: These results, after a follow up of 3 months, evidence a remarkable improvement in seizure control when treating patients with focal refractory epilepsy. The presence of adverse events was frequent.